TY  - JOUR
AU  - Funk, Cornelius
AU  - Ehlers, Anna
AU  - Orth, Martin F
AU  - Aljakouch, Karim
AU  - Li, Jing
AU  - Hoelting, Tilman Lb
AU  - Will, Rainer
AU  - Geyer, Florian H
AU  - Ceranski, A Katharina
AU  - Willis, Franziska
AU  - Vinca, Endrit
AU  - Ohmura, Shunya
AU  - Imle, Roland
AU  - Siebenlist, Jana
AU  - Yershova, Angelina
AU  - Knott, Maximilian Ml
AU  - Zahnow, Felina
AU  - Sastre, Ana
AU  - Alonso, Javier
AU  - Sahm, Felix
AU  - Peterziel, Heike
AU  - Loboda, Anna
AU  - Schneider, Martin
AU  - Banito, Ana
AU  - Leprivier, Gabriel
AU  - Hartmann, Wolfgang
AU  - Dirksen, Uta
AU  - Witt, Olaf
AU  - Oehme, Ina
AU  - Pfister, Stefan M
AU  - Romero-Pérez, Laura
AU  - Krijgsveld, Jeroen
AU  - Cidre-Aranaz, Florencia
AU  - Grünewald, Thomas
AU  - Musa, Julian
TI  - High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma.
JO  - The journal of clinical investigation
VL  - nn
SN  - 0021-9738
CY  - Ann Arbor, Mich.
PB  - ASCJ
M1  - DKFZ-2025-02146
SP  - nn
PY  - 2025
N1  - #EA:B410#LA:B410# / epub
AB  - Chromosome 8 (chr8) gains are common in cancer, but their contribution to tumor heterogeneity is largely unexplored. Ewing sarcoma (EwS) is defined by FET::ETS fusions with few other recurrent mutations to explain clinical diversity. In EwS, chr8 gains are the second most frequent alteration, making it an ideal model to study their relevance in an otherwise silent genomic context. We report that chr8 gain-driven expression patterns correlate with poor overall survival of EwS patients. This effect is mainly mediated by increased expression of the translation initiation factor binding protein 4E-BP1, encoded by EIF4EBP1 on chr8. Among all chr8-encoded genes, EIF4EBP1 expression showed the strongest association with poor survival and correlated with chr8 gains in EwS tumors. Similar findings emerged across multiple TCGA cancer entities. Multi-omics profiling revealed that 4E-BP1 orchestrates a pro-proliferative proteomic network. Silencing 4E-BP1 reduced proliferation, clonogenicity, spheroidal growth in vitro, and tumor growth in vivo. Drug screens demonstrated that high 4E-BP1 expression sensitizes EwS to pharmacological CDK4/6-inhibition. Chr8 gains and elevated 4E-BP1 emerge as prognostic biomarkers in EwS, with poor outcomes driven by 4E-BP1-mediated pro-proliferative networks that sensitize tumors to CDK4/6 inhibitors. Testing for chr8 gains may enhance risk stratification and therapy in EwS and other cancers.
KW  - Cancer (Other)
KW  - Genetic variation (Other)
KW  - Genetics (Other)
KW  - Mouse models (Other)
KW  - Oncology (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41100815
DO  - DOI:10.1172/JCI187627
UR  - https://inrepo02.dkfz.de/record/305417
ER  -